Monte Rosa Therapeutics (GLUE) Current Leases (2022 - 2026)

Monte Rosa Therapeutics' Current Leases history runs 5 years deep, the most recent figure standing at $4.5 million for Q1 2026.

• In Q1 2026, Current Leases rose 15.99% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $4.5 million (up 15.99% YoY), while the FY2025 annual figure was $4.4 million, up 18.39% from the prior year.
• Current Leases for Q1 2026 stood at $4.5 million, up from $4.4 million in the prior quarter.
• The five-year high for Current Leases was $4.5 million in Q1 2026, with the low at $2.7 million in Q2 2022.
• The 5-year median for Current Leases is $3.4 million (2024), against an average of $3.5 million.
• The sharpest annual moves came in 2023 and 2024: Current Leases fell 6.0% in 2023, then jumped 30.15% in 2024.
• Monte Rosa Therapeutics' Current Leases stood at $3.1 million in 2022, then grew by 1.12% to $3.2 million in 2023, then grew by 17.46% to $3.7 million in 2024, then climbed by 18.39% to $4.4 million in 2025, then increased by 1.96% to $4.5 million in 2026.
• Business Quant data shows GLUE's Current Leases at $4.5 million in Q1 2026, $4.4 million in Q4 2025, and $4.2 million in Q3 2025.